135 related articles for article (PubMed ID: 33370727)
21. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
de Mestier L; Védie AL; Faron M; Cros J; Rebours V; Hentic O; Do Cao C; Bardet P; Lévy P; Sauvanet A; Ruszniewski P; Hammel P
Neuroendocrinology; 2020; 110(11-12):967-976. PubMed ID: 31791037
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
23. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
24. Lymphovascular Invasion Predicts Lymph Node Involvement in Small Pancreatic Neuroendocrine Tumors.
Blakely AM; Lafaro KJ; Li D; Kessler J; Chang S; Ituarte PHG; Lee B; Singh G
Neuroendocrinology; 2020; 110(5):384-392. PubMed ID: 31401633
[TBL] [Abstract][Full Text] [Related]
25. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Recurrence in Pancreatic Neuroendocrine Tumor and Size as a Surrogate in Determining the Treatment Strategy: A Korean Nationwide Study.
Kwon W; Jang JY; Song KB; Hwang DW; Kim SC; Heo JS; Choi DW; Hwang HK; Kang CM; Yoon YS; Han HS; Park JS; Hong TH; Cho CK; Ahn KS; Lee H; Lee SE; Jeong CY; Roh YH; Kim HJ;
Neuroendocrinology; 2021; 111(8):794-804. PubMed ID: 33002889
[TBL] [Abstract][Full Text] [Related]
27. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis.
Du B; Wang X; Zhang W; Tan Q; Wei Y; Shao Z
ANZ J Surg; 2022 Apr; 92(4):787-793. PubMed ID: 34723424
[TBL] [Abstract][Full Text] [Related]
28. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
[TBL] [Abstract][Full Text] [Related]
30. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors.
Chouliaras K; Newman NA; Shukla M; Swett KR; Levine EA; Sham J; Mann GN; Shen P
J Surg Oncol; 2018 Sep; 118(3):416-421. PubMed ID: 30259518
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
[TBL] [Abstract][Full Text] [Related]
32. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
[TBL] [Abstract][Full Text] [Related]
33. Time-trend and recurrence analysis of pancreatic neuroendocrine tumors.
Kim H; Song KB; Hwang DW; Lee JH; Alshammary S; Kim SC
Endocr Connect; 2019 Jul; 8(7):1052-1060. PubMed ID: 31252400
[TBL] [Abstract][Full Text] [Related]
34. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.
Tsang ES; McConnell YJ; Schaeffer DF; Yin Y; Speers CH; Kennecke HF
Dis Colon Rectum; 2018 Feb; 61(2):187-192. PubMed ID: 29337773
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
37. Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and Where?
Marchegiani G; Landoni L; Andrianello S; Masini G; Cingarlini S; D'Onofrio M; De Robertis R; Davì M; Capelli P; Manfrin E; Amodio A; Paiella S; Malleo G; Damoli I; Miotto M; Bianchi B; Nessi C; Vivani E; Scarpa A; Salvia R; Bassi C
Neuroendocrinology; 2019; 108(3):161-171. PubMed ID: 30481765
[TBL] [Abstract][Full Text] [Related]
38. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).
Viúdez A; Carvalho FL; Maleki Z; Zahurak M; Laheru D; Stark A; Azad NS; Wolfgang CL; Baylin S; Herman JG; De Jesus-Acosta A
Oncotarget; 2016 May; 7(18):24950-61. PubMed ID: 26894863
[TBL] [Abstract][Full Text] [Related]
39. Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study.
Zou S; Jiang Y; Wang W; Zhan Q; Deng X; Shen B
Int J Surg; 2020 Feb; 74():86-91. PubMed ID: 31926324
[TBL] [Abstract][Full Text] [Related]
40. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
